McNamara Peter sold $2K of TECX

Tectonic Therapeutic (TECX) reported Q2 results, highlighting progress in two clinical trials, TX45 for pulmonary hypertension and TX2100 for a rare bleeding disorder. The company has sufficient cash to fund operations into 2029. Net loss widened to $22.3M from $20M a year earlier. Hedge fund ownership increased, while short interest remains high at 17.86% of the float.

Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-

Tectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.

Control Empresarial de Capitales S.A. de C.V. sold 1,381,000 shares of TALOS ENERGY INC. (TALO) at an average of $18.52 ($18.52–$18.61, $25.58M total) across 2 trades on 2026-09-15.

Brille Brian J (See Remarks) sold 400,000 shares of Caris Life Sciences, Inc. (CAI) at $30.33 ($12.13M total) on 2026-09-17.

SL SPV-2, L.P. sold 46,990 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.79 ($542.78–$564.46, $25.98M total) across 22 trades on 2026-09-15. Filed jointly with SLTA SPV-2, L.P. (Director), SLTA SPV-2 (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).